PrognomiQ announced the launch of ProVue Lung, a novel blood-based Laboratory Developed Test (LDT) designed to help improve detection of lung cancer at its earliest, most treatable stages.
The launch represents the initial commercial availability of ProVue Lung and the first step in PrognomiQ’s broader commercialization strategy. As part of this milestone, PrognomiQ has signed agreements with Allegheny Health Network and Lung Innovations Network at Penn Highlands Healthcare, which will begin offering ProVue Lung through an Early Experience Program at locations across Pennsylvania to evaluate how the test can be best integrated into clinical workflows for lung cancer screening.
In a series of clinical studies that informed PrognomiQ's pending publication, ProVue Lung has been shown to detect lung cancer with 85% sensitivity and 55% specificity. Importantly, Stage I lung cancer is detected at 81% sensitivity, when treatment is most effective. The test also has a clinically informative negative predictive value (NPV) of greater than 99.8 percent.
Designed for high-risk adults 50 years of age and older with a smoking history of 20 or more packs a year, the test uses a simple blood draw to reduce barriers to screening and integrates into existing workflows – helping more patients to receive the care they need.
Read PrognomiQ’s announcement here
